| Symbol | AORT |
|---|---|
| Name | ARTIVION, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Medical/Dental Instruments |
| Address | 1655 ROBERTS BOULEVARD NORTH WEST, KENNESAW, Georgia, 30144, United States |
| Telephone | +1 770 419-3355 |
| Fax | — |
| — | |
| Website | https://www.artivion.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0000784199 |
| Description | Artivion is a leader in the manufacturing processing and distribution of medical devices and implantable tissues used in cardiac and vascular surgical procedures focused on aortic repair. Our purpose is to develop simple elegant solutions that address cardiac and vascular surgeons most difficult challenges in treating patients with diseases of the aorta and deliver breakthrough technologies of unsurpassed quality that have far-reaching impact. Our decades of expertise in treating aortic diseasescoupled with our recent acquisitions and partnershipshave empowered us to offer cardiac and vascular surgeons a suite of aortic-centric solutions such as cryopreserved cardiac and vascular allografts surgical sealants prosthetic heart valves and aortic stents and stent-grafts. Artivion has over 1250 employees worldwide with sales representation in over 100 countries. The Company has manufacturing facilities located in Atlanta Georgia Austin Texas and Hechingen Germany. Additional info from NASDAQ: |
Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results
Read moreGREEN ANDREW M 🟡 adjusted position in 44.0K shares (2 derivative) of ARTIVION, INC. (AORT) at $20.71 ($2.1M) Transaction Date: Jun 11, 2026 | Filing ID: 043059
Read moreNew Form 3 - ARTIVION, INC. <b>Filed:</b> 2026-06-08 <b>AccNo:</b> 0001628280-26-041704 <b>Size:</b> 215 KB
Read moreDirector SEMEDO ANTHONY B. 🟡 adjusted position in 0 shares of ARTIVION, INC. (AORT) Transaction Date: Jun 02, 2026 | Filing ID: 040860
Read moreNew Form SD - ARTIVION, INC. <b>Filed:</b> 2026-05-21 <b>AccNo:</b> 0001628280-26-037127 <b>Size:</b> 58 KB
Read moreDirector SEMEDO ANTHONY B. 🟢 acquired 7.6K shares of ARTIVION, INC. (AORT) Transaction Date: May 18, 2026 | Filing ID: 037008
Read moreDirector Salveson Jon W 🟢 acquired 7.6K shares of ARTIVION, INC. (AORT) Transaction Date: May 18, 2026 | Filing ID: 037006
Read moreDirector Hoff Elizabeth A 🟢 acquired 7.6K shares of ARTIVION, INC. (AORT) Transaction Date: May 18, 2026 | Filing ID: 037004
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07413926 | Mitral Valve Repair With the Chord-X System: A Long Term Evaluation | — | Mitral Regurgitation (MR) | Not_Yet_Recruiting | 2026-06-01 | 2034-06-01 | ClinicalTrials.gov |
| NCT07089576 | Clinical Study to Evaluate the Safety and Effectiveness of Arcevo LSA | Na | Aortic Arch Aneurysm | Recruiting | 2025-11-04 | 2032-07-01 | ClinicalTrials.gov |
| NCT05174767 | PERSEVERE- A Trial to Evaluate AMDS in Acute DeBakey Type I Dissection | Na | Acute Aortic Dissection | Active_Not_Recruiting | 2022-05-27 | 2029-12-06 | ClinicalTrials.gov |
| NCT05314868 | Retrospective Evaluation of Photo-oxidized Decellularized Bovine Pericardium in… | — | Congenital Heart Disease | Terminated | 2022-03-31 | 2022-11-30 | ClinicalTrials.gov |
| NCT04142658 | PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can … | Phase3 | Aortic Valve Disease | Terminated | 2020-05-01 | 2022-12-12 | ClinicalTrials.gov |
| NCT03669042 | Post-market, Prospective Evaluation of PHOTO-oxidized Bovine Pericardium in Vas… | Na | Vascular Diseases | Completed | 2018-11-20 | 2020-07-10 | ClinicalTrials.gov |
| NCT03397251 | DARTS I: Feasibility, Safety, and Performance Trial | Na | Acute DeBakey I Aortic Dissection | Completed | 2018-03-07 | 2024-01-23 | ClinicalTrials.gov |
| NCT03035643 | DARTS I Feasibility Study | Na | Aortic Dissection | Completed | 2017-03-05 | 2024-03-19 | ClinicalTrials.gov |
| NCT02359994 | Prospective, Multicenter, Multidisciplinary, Controlled Clinical Investigation … | Na | Blood Loss, Surgical | Completed | 2015-04-01 | 2019-02-20 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Arcevo™ LSA Hybrid Stent Graft System | Other | Approved | Aortic Arch Aneurysm | RECRUITING | NCT07089576 |
| Arcevo™ LSA Hybrid Stent Graft System | Other | Approved | Aortic Arch Aneurysm | RECRUITING | NCT07089576 |
| Arcevo™ LSA Hybrid Stent Graft System | Other | Approved | Aortic Arch Aneurysm | RECRUITING | NCT07089576 |
| Arcevo™ LSA Hybrid Stent Graft System | Other | Approved | Aortic Arch Aneurysm | RECRUITING | NCT07089576 |
| Arcevo™ LSA Hybrid Stent Graft System | Other | Approved | Aortic Arch Aneurysm | RECRUITING | NCT07089576 |
| Arcevo™ LSA Hybrid Stent Graft System | Other | Approved | Aortic Arch Aneurysm | RECRUITING | NCT07089576 |
| Arista AH | Other | Approved | Blood Loss, Surgical | COMPLETED | NCT02359994 |
| PerClot Polysaccharide Hemostatic System | Other | Approved | Blood Loss, Surgical | COMPLETED | NCT02359994 |
| PhotoFix | Other | Preclinical | Congenital Heart Disease | TERMINATED | NCT05314868 |
| On-X Aortic Mechanical Valve | Other | Phase PHASE3 | Aortic Valve Disease | TERMINATED | NCT04142658 |
| Warfarin | Other | Phase PHASE3 | Aortic Valve Disease | TERMINATED | NCT04142658 |
| Apixaban 2.5 MG | Other | Phase PHASE3 | Aortic Valve Disease | TERMINATED | NCT04142658 |
| Apixaban 5 MG | Other | Phase PHASE3 | Aortic Valve Disease | TERMINATED | NCT04142658 |
| AMDS | Other | Approved | Acute DeBakey I Aortic Dissection | COMPLETED | NCT03397251 |
| AMDS | Other | Approved | Aortic Dissection | COMPLETED | NCT03035643 |
| PhotoFix | Other | Approved | Vascular Diseases | COMPLETED | NCT03669042 |
| AMDS | Other | Approved | Acute Aortic Dissection | ACTIVE_NOT_RECRUITING | NCT05174767 |
| Arcevo™ LSA Hybrid Stent Graft System | Other | Approved | Aortic Arch Aneurysm | RECRUITING | NCT07089576 |
| Arcevo™ LSA Hybrid Stent Graft System | Other | Approved | Aortic Arch Aneurysm | RECRUITING | NCT07089576 |
| Arcevo™ LSA Hybrid Stent Graft System | Other | Approved | Aortic Arch Aneurysm | RECRUITING | NCT07089576 |
| Arcevo™ LSA Hybrid Stent Graft System | Other | Approved | Aortic Arch Aneurysm | RECRUITING | NCT07089576 |
| Arcevo™ LSA Hybrid Stent Graft System | Other | Approved | Aortic Arch Aneurysm | RECRUITING | NCT07089576 |
| Arcevo™ LSA Hybrid Stent Graft System | Other | Approved | Aortic Arch Aneurysm | RECRUITING | NCT07089576 |
| Arcevo™ LSA Hybrid Stent Graft System | Other | Approved | Aortic Arch Aneurysm | RECRUITING | NCT07089576 |
| Chord-X system implant | DEVICE | Preclinical | Mitral Regurgitation (MR) | NOT_YET_RECRUITING | NCT07413926 |
| Arcevo™ LSA Hybrid Stent Graft System | DEVICE | Approved | Aortic Arch Aneurysm | RECRUITING | NCT07089576 |
| On-X Aortic Mechanical Valve | DEVICE | Phase PHASE3 | Aortic Valve Disease | TERMINATED | NCT04142658 |
| Warfarin | DRUG | Phase PHASE3 | Aortic Valve Disease | TERMINATED | NCT04142658 |
| Apixaban 2.5 MG | DRUG | Phase PHASE3 | Aortic Valve Disease | TERMINATED | NCT04142658 |
| Apixaban 5 MG | DRUG | Phase PHASE3 | Aortic Valve Disease | TERMINATED | NCT04142658 |
| PhotoFix | DEVICE | Preclinical | Congenital Heart Disease | TERMINATED | NCT05314868 |
| AMDS | DEVICE | Approved | Acute Aortic Dissection | ACTIVE_NOT_RECRUITING | NCT05174767 |
| Arista AH | DEVICE | Approved | Blood Loss, Surgical | COMPLETED | NCT02359994 |
| PerClot Polysaccharide Hemostatic System | DEVICE | Approved | Blood Loss, Surgical | COMPLETED | NCT02359994 |